ARS-1620

製品コードS8707 バッチS870702

化学情報

	Synonyms	N/A	Storage (From the date of receipt)	3 years -20°C powder
	化学式	C₂₁H₁₇ClF₂N₄O₂
	分子量	430.84	CAS No.	1698055-85-4
Solubility (25°C)*	体外	DMSO	86 mg/mL (199.61 mM)
		Ethanol	32 mg/mL (74.27 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	ARS-1620 is a potent, orally bioavailable covalent inhibitor of KRAS^G12C) and could achieve rapid and sustained in vivo target occupancy to induce tumor regression.
in vitro	ARS-1620 covalently inhibits KRAS (G12C) activity with high potency and atropisomeric selectivity in p.G12C mutant cancer cells. ARS-1620 rapidly engaged G12C in a concentration- and time- dependent manner consistent with its covalent mechanism of inhibition. Across a panel of cell lines harboring the mutant allele, ARS-1620 exhibited a half maximal G12C target engagement (TE50) at ~0.3 μM and near complete engagement at 3.0 μM after 2 hr of treatment. RS-1620 inhibits RAS-GTP and the phosphorylation of MEK, ERK, RSK, S6, and AKT in a dose-dependent and selective manner in H358 (p.G12C) but not in negative control lung cancer cell lines lacking p.G12C (A549, H460, and H441). ARS-1620 elicits sub-micromolar allele-specific potency (IC50 = 0.3 μM; IC90 = 1 μM). The activity of ARS-1620 is specific to the G12C allele and mediated by the covalent modification of Cys-12^[1].
in vivo	ARS-1620 exhibits excellent oral bioavailability (F > 60%) in mice. In MIA-PaCa2 xenografts (p.G12C), ARS-1620 significantly inhibits tumor growth (p < 0.001) in a dose-dependent manner with marked regression at a dose of 200 mg/kg, given once daily. Xenografts of H441 (p.G12V) lack a response at all doses tested and the R-atropisomer of ARS-1620 lacks activity in both models. ARS-1620 selectively induces tumor regression in patient-derived tumor models (harboring KRAS p.G12C)^[1].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	H358 cells
	濃度	4 μM
	反応時間	4 h
	実験の流れ	Cells are maintained in a humidified incubator at 37 C with 5% CO2, and grown in RPMI 1640 or DMEM supplemented with 10% FBS and 50 IU ml-1 penicillin/streptomycin.
動物実験	動物モデル	6- to 8-week-old male BALB/c mice
	投薬量	2 and 10 mg/kg
	投与方法	intravenous (IV) bolus or oral gavage administration

参考

[1] Janes MR, et al. Cell. 2018, 172(3):578-589.e17.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer [ Nat Commun, 2024, 15(1):3741]	PubMed: 38702301
Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells [ Cell Death Dis, 2024, 15(1):56]	PubMed: 38225225
Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling [ bioRxiv, 2024, 2024.09.26.615226]	PubMed: 39386679
Therapy-induced APOBEC3A drives evolution of persistent cancer cells [ Nature, 2023, 620(7973):393-401]	PubMed: 37407818
Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer [ Int J Mol Sci, 2023, 24(2)997]	PubMed: 36674513
Creating MHC-restricted neoantigens with covalent inhibitors that can be targeted by immune therapy [ Cancer Discov, 2022, CD-22-1074]	PubMed: 36250888
KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy [ Cell Rep, 2022, 39(12):110993]	PubMed: 35732135
Development of a biotin-streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRASG12C inhibitors [ SLAS Discov, 2022, 27(2):107-113]	PubMed: 35058184
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation [ Cancer Discov, 2021, 11(8):1913-1922]	PubMed: 33824136
Selective and noncovalent targeting of RAS mutants for inhibition and degradation [ Nat Commun, 2021, 12(1):2656]	PubMed: 33976200

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。